Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges [Yahoo! Finance]
Omeros Corporation (OMER)
Last omeros corporation earnings: 3/2 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.omeros.com
Company Research
Source: Yahoo! Finance
trial results for its treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) using narsoplimab. The study showed a three-fold lower death risk for patients treated with narsoplimab compared to those who didn't receive the treatment. The company plans to resubmit its Biologics License Application to the FDA and apply for a marketing license with the European Medicines Agency in 2025, with the goal of making narsoplimab the first approved therapy for TA-TMA, a condition with few current treatment options. Generated by Yahoo Finance AI Yahoo Finance used generative AI to summarize key information from this article. Some details may be inaccurate. We take that seriously. Reporting mistakes helps us improve these summaries. Was this helpful? Yes No As of the latest noted price at the time of writing, Omeros Corporation's ( OMER Financials ) stock price jumped to $12.54, up $5.08 or 68.1%. The rise corresponds with the announcement that it
Show less
Read more
Impact Snapshot
Event Time:
OMER
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OMER alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OMER alerts
High impacting Omeros Corporation news events
Weekly update
A roundup of the hottest topics
OMER
News
- Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMABusiness Wire
- Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual MeetingBusiness Wire
- Omeros Corporation Announces Upcoming Presentations at ASH Annual MeetingBusiness Wire
OMER
Earnings
- 5/15/24 - Miss
OMER
Sec Filings
- 12/19/24 - Form 8-K
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- OMER's page on the SEC website